Contradictory research about the diabetes drug Avandia has surfaced this week. Two reports out Monday and published in the Journal of the American Medical Association and the Archives of Internal Medicine found that the drug increased the risk of heart trouble when compared to a placebo or Actos. However, a smaller study suggests the drug does not increase--and may even decrease--cardiovascular risks.